FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Jörg Hielscher et al.|The Lancet Oncology|2014Cited by 1.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Dominik Paul Modest et al.|The Lancet Oncology|2016Cited by 417
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)Christoph Rageth, Zsuzsanna Varga, Elizabeth O’Flynn et al.|Breast Cancer Research and Treatment|2016Cited by 264
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)Christoph Rageth, Zsuzsanna Varga, Elizabeth O’Flynn et al.|Breast Cancer Research and Treatment|2018Cited by 251
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialSebastian Stintzing, Volker Heinemann, Pratyaksha Wirapati et al.|Annals of Oncology|2019Cited by 194